Soligenix Reports 2025 Results with Phase 3 CTCL Trial Progress and Orphan Drug Designation

Soligenix reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for dusquetide in Behcet's Disease, ongoing development of SGX302 and SGX945 programs and a year-end cash position of approximately $7.9 million, as it continues to pursue strategic options to support late-stage development.

The advancement of the Phase 3 FLASH2 trial represents a critical milestone for patients with cutaneous T-cell lymphoma, a rare cancer with limited treatment options. HyBryte, also known as SGX301 or synthetic hypericin sodium, is being developed as a novel photodynamic therapy utilizing safe visible light. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. This development matters because it addresses a significant unmet medical need in oncology, offering a potentially safer alternative to existing treatments that often involve more toxic approaches.

The orphan drug designation for dusquetide in Behcet's Disease represents another important regulatory achievement for Soligenix. Orphan drug status provides incentives for developing treatments for rare diseases, including market exclusivity and potential tax credits, which can accelerate development timelines. This designation is particularly significant for Behcet's Disease patients, who currently have limited therapeutic options for managing this chronic inflammatory condition that can affect multiple organ systems.

Soligenix's development programs extend beyond these key initiatives, including expansion of synthetic hypericin into psoriasis and development of dusquetide for inflammatory diseases such as oral mucositis in head and neck cancer. The company's Public Health Solutions business segment includes vaccine development programs supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency and the Biomedical Advanced Research and Development Authority. These programs incorporate proprietary heat stabilization platform technology known as ThermoVax, which could have implications for vaccine stability and distribution in challenging environments.

The company's financial position, with approximately $7.9 million in cash at year-end 2025, provides resources to continue advancing these programs while pursuing strategic options to support late-stage development. The progress reported in these results demonstrates Soligenix's commitment to addressing rare diseases with significant unmet medical needs, potentially bringing new treatment options to patient populations that have been historically underserved by pharmaceutical development. The implications of these developments extend beyond individual patients to healthcare systems that bear the burden of managing complex rare diseases with limited therapeutic alternatives.